ROL' IMMUNOKON\"YuGATOV V TARGETNOY TERAPII ZLOKAChESTVENNYKh OPUKhOLEY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Amplification or overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 25 % of cases of breast cancer (BC). Trastuzumab is a recombinant humanized monoclonal antibody against HER2, which is effective as monotherapy and improves the results of chemotherapy for HER2-positive metastatic and resectable breast cancer. The article presents the results of phase I-II study of trastuzumab-DMI (T-DM1),a new immunoconjugate of monoclonal antibodies, and maytansinoid DM1 (ADC) in patients with ER2 + metastatic BC.

Full Text

Restricted Access

References

  1. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvanttrastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. San Antonio Breast Cancer Symposium. 2008.
  2. Semiglazov V., Eiermann W., Manikhas A., et al. Surgical aspects of the NOAH phase III trial (neoadjuvanttrastuzumab[Herceptin] in HER2-positive locally advanced breast cancer). Eur J Cancer 2008;6(7): 115 [abstract 400].
  3. Larson R.A., Sievers E.L., Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumaboxogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104: 1442-52.
  4. Chari R.V. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107.
  5. Senter P.D. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44.
  6. Smith A.L., Nicolaou K.S. The enediyne antibiotics. J Med Chem 1996;39:2103-17.
  7. Widdison W.C., Wilhelm S.D., Cavanagh E.E., et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408.
  8. Doronina S.O., Bovee T.D., Meyer D.W., et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 2008;19:1960-63.
  9. Pastan I., Hassan R., FitGerald D.J., et al. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
  10. Kreitman R.J., Steiler-Stevenson M., Margulies I., et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983-90.
  11. Lewis Phillips G.D., Li G., Dugger D.L., et al. Targeting HER-2-positive breast cancer with trastuzumab-DMl, and antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
  12. Beeram M., Burns H.A. III, Modi S., et al. A phase I study of trastuzumab-DMl (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients Opts) with advanced HER2+ breast cancer. J Clin Oncol 2008;33:2028.
  13. Vogel C.I., Burris H.A., Limentani S., et al. A phate II study of trastuxumab-DMl (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. J Clin Oncol 2009;27:101 7.
  14. Krop I., LoRusso P., Miller K.D., et al. A phase II study of trastuzumab- DMl (T-DM1), a novel HER2 antibody-drug conjugate, in patients previously treated with lapatinib, trastuzumab and chemotherapy. San Antonio Breast Cancer Symp 2009, Dec. 9-13 [Abstr. 5090].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies